Biotech2 weeks ago
Roche Buys Poseida Therapeutics for $1.5 Billion
Roche is acquiring Poseida Therapeutics for up to $1.5 billion, emphasizing its strategic focus on innovative allogeneic CAR-T cancer therapies. Poseida’s candidate P-BCMA-ALLO1 shows promise in...